Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.

PloS one - 1 Jan 2016

Tanino Hirokazu, Kosaka Yoshimasa, Nishimiya Hiroshi, Tanaka Youko, Minatani Naoko, Kikuchi Mariko, Shida Akiko, Waraya Mina, Katoh Hiroshi, Enomoto Takumo, Sengoku Norihiko, Kajita Sabine, Hoffman Robert M, Watanabe Masahiko

Abstract excerpt

BRCAness is defined as the set of traits in which BRCA1 dysfunction, arising from gene mutation, methylation or deletion, results in DNA repair deficiency. In the present study, we addressed BRCAness, therapeutic efficacy, recurrence, and survival in patients with triple negative breast cancer (TNBC) who were treated with neoadjuvant chemotherapy at Kitasato University Hospital, Japan, between April 2006 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anthracyclines
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoadjuvant Therapy

Share to Neoplasm Recurrence, Local

Share to Remission Induction

Share to Survival Analysis

Share to Taxoids

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 27935989
DOI: 10.1371/journal.pone.0165721
PMCID: PMC5147808

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.PMID 27935989Read ↗

BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer.Semantic proximity Read ↗

BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.Semantic proximity Read ↗

Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes.Semantic proximity Read ↗

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriersSemantic proximity Read ↗

Association of BRCA Mutations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell LinesSemantic proximity Read ↗

Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic AnalysisSemantic proximity Read ↗

Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancersSemantic proximity Read ↗

Molecular Classification and Future Therapeutic Challenges of Triple-negative Breast CancerSemantic proximity Read ↗

Germline Mutations Related to Complete Remission after Neoadjuvant Chemotherapy in Patients with Triple-negative Breast CancerSemantic proximity Read ↗

BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients.Semantic proximity Read ↗

Biology and Management of Patients With Triple-Negative Breast CancerSemantic proximity Read ↗

BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.